| 566.4 | 531.3 | 488.2 | 441.5 | 401.1 | 358.8 | | | | | | | | |
| 41.2% | 48.1% | 64.4% | 82.7% | 109.1% | 137.5% | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| 224.9 | 213.6 | 197.9 | 179.5 | 163.1 | 141 | | | | | | | | |
Cost of Net Product Revenue | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| 341.4 | 317.7 | 290.3 | 262.1 | 238 | 217.8 | | | | | | | | |
| | | | | | | | | | | | | | |
| 60.3% | 59.8% | 59.5% | 59.4% | 59.3% | 60.7% | | | | | | | | |
Selling, General & Administrative Expenses | 180.6 | 177.3 | 176.1 | 168.6 | 156.3 | 144.3 | | | | | | | | |
Selling, General and Administrative | | | | | | | | | | | | | | |
Research & Development Expenses | 64.8 | 63.8 | 61.7 | 56 | 50.3 | 47.1 | | | | | | | | |
Research, Development and Clinical Trials | | | | | | | | | | | | | | |
Acquired in-Process Research and Development Expenses | | | | | | | | | | | | | | |
| 96 | 76.6 | 52.5 | 37.5 | 31.5 | -0.8 | | | | | | | | |
| | | | | | | | | | | | | | |
| 16.9% | 14.4% | 10.8% | 8.5% | 7.8% | -0.2% | | | | | | | | |
Interest and Investment Income | — | — | — | 12.7 | — | — | | | | | | | | |
Interest Income and Other Income, Net | | | | | | | | | | | | | | |
| -14 | -14.1 | -14.3 | -14.4 | -14.4 | -14.4 | | | | | | | | |
| | | | | | | | | | | | | | |
| — | — | — | — | — | — | | | | | | | | |
Change in Fair Value of Preferred Stock Warrant Liability | | | | | | | | | | | | | | |
Total Non-Operating Income | -14 | -14.1 | -14.3 | -1.7 | -14.4 | -14.4 | | | | | | | | |
Income Before Provision for Income Taxes | 92.9 | 74.1 | 50.1 | 35.8 | 32.7 | 1.5 | | | | | | | | |
Income Before Income Taxes | | | | | | | | | | | | | | |
Provision for Income Taxes | 1.1 | 2.4 | 1.1 | 0.3 | 0 | -1.5 | | | | | | | | |
(Provision) Benefit for Income Taxes | | | | | | | | | | | | | | |
| 91.8 | 71.7 | 48.9 | 35.5 | 32.6 | 3 | | | | | | | | |
| | | | | | | | | | | | | | |
Net Income Attributable to Common Shareholders | 91.8 | 71.7 | 48.9 | 35.5 | 32.6 | 3 | | | | | | | | |
| | | | | | | | | | | | | | |
| 2.7 | 2.1 | 1.5 | 1.1 | 1 | 0.1 | | | | | | | | |
| 2.5 | 1.9 | 1.4 | 1 | 0.9 | 0 | | | | | | | | |
Basic Weighted Average Shares Outstanding | 33.8 | 33.7 | 33.5 | 33.2 | 33 | 32.8 | | | | | | | | |
| 34.1 | 34 | 33.8 | 33.6 | 33.6 | 33.3 | | | | | | | | |
Diluted Weighted Average Shares Outstanding | 39.1 | 37.8 | 36.5 | 35.2 | 35 | 34.2 | | | | | | | | |
| 121.4 | 100.3 | 74.1 | 57.3 | 49.1 | 13.6 | | | | | | | | |
| 1.2% | 3.3% | 2.2% | 0.9% | 0% | -102.7% | | | | | | | | |